Drug intelligence / Profile preview

kami-untan-to + donepezil

Development stage
Unknown
Modality
Small Molecules
Administration
Oral
01

Overview

Kami-Untan-To + donepezil is a combination therapy consisting of Kami-Untan-To (also known as Kamiuntanto or KUT), a traditional Japanese Kampo herbal medicine, and donepezil, an acetylcholinesterase inhibitor. This combination has been studied for its potential synergistic effects in the treatment of Alzheimer's disease and dementia. Kami-Untan-To is composed of 13 crude herbal ingredients and is known to upregulate choline acetyltransferase (ChAT) expression and nerve growth factor mRNA levels in the brain, potentially enhancing cholinergic neurotransmission[2][4][6]. Donepezil works by inhibiting acetylcholinesterase, thereby increasing acetylcholine levels in the brain to improve cognitive function. Clinical studies suggest that combining these two agents may provide greater cognitive benefits than either agent alone and may increase cerebral blood flow in patients with Alzheimer's disease[5]. The combination represents an integration of Western pharmaceutical therapy with traditional Japanese medicine.

Other names
kamiuntanto + donepezilkami untan to + donepezilKUT + donepezil
02

Targets

NGF (Nerve growth factor)CHAT (Choline acetyltransferase)Acetylcholinesterase

Beyond the preview

Go deeper on kami-untan-to + donepezil.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on kami-untan-to + donepezil.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call